Home/Database/BMS-202
Immune SupportPre-clinical

BMS-202

Small-molecule PD-L1 dimerization inhibitor BMS-202

N/A Amino Acids · MW: N/A

Amino Acids

N/A

Molecular Weight

N/A

Half-life

Unknown

Research Score

4.1

Studies

60

Storage

Store lyophilized at -20°C, reconstituted at 2-8°C

What is BMS-202?

BMS-202 is a benzimidazole-based research compound that inhibits the PD-1/PD-L1 interaction by stabilizing PD-L1 homodimers. It is widely used as a tool molecule in checkpoint biology and immuno-oncology screening.

Key Benefits & Mechanisms

PD-L1 inhibition

checkpoint pathway mapping

T-cell restoration research

combination screening

Research Summary

BMS-202 helped validate the concept that small molecules can directly block PD-L1-mediated immune evasion. It remains a preclinical reference compound rather than a clinical drug.